MedTrace Logo

Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

NCT03434912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-08-16

No results posted yet for this study

Summary

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Conditions

  • CTC and Tumor Related Rare Cell

Sponsors & Collaborators

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • MiCareo Taiwan Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2018-12-30
Completion
2020-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03434912 on ClinicalTrials.gov